Home Infusion Therapy Industry Overview

The global home infusion therapy market size was valued at USD 35.96 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2024 to 2030.

Home infusion therapy involves delivering therapeutic treatments, medications, or fluids directly into a patient's bloodstream through intravenous (IV) infusion, usually in the comfort and convenience of their home.

The growth of the market is driven by several key factors, including the expanding geriatric population characterized by decreased mobility, a rising preference for home care, and the swift evolution of technological advancements. Infusion therapy, encompassing essential components like IV therapy and IV hydration therapy, plays a crucial role in addressing conditions such as immune deficiencies, cancer, and congestive heart failure, where oral medication is not a viable treatment option. The increasing demand for these therapies stems from the need for long-term treatment among patients, positioning home infusion therapy as a notably cost-effective alternative to hospital-based care. The incorporation of IV therapy and IV hydration therapy serves as a driving force, providing patients with enhanced accessibility to effective and personalized medical solutions in the comfort of their homes

Gather more insights about the market drivers, restrains and growth of the Home Infusion Therapy Market

The home infusion market experienced a positive shift during the COVID-19 pandemic, with home infusion becoming a crucial necessity as healthcare facilities faced a surge in COVID patients. Despite the challenges posed by regional and country-wide lockdowns, causing disruptions in operations and supply chains, the market witnessed a substantial increase in 2020. As reported by Medtech Dive in October 2020, Baxter disclosed third-quarter sales of USD 2.97 billion, marking a 4% growth attributed to the rising demand for its COVID-related medical products. Furthermore, Baxter reported operational sales growth of 6% (reaching 3.2 billion) in Q3 2021 compared to 3.0 billion in Q3 2020, indicating a sustained recovery from the pandemic's impact.

Moreover, the market's expansion is propelled by the enhanced outcomes observed in patients and the cost-effectiveness and convenience provided by home infusion therapy. The increasing demographic of baby boomers struggling with diminished mobility due to conditions such as paralysis, osteoarthritis, and diabetes is expected to amplify the demand for home infusion therapy. The growing imperative to reduce the duration of inpatient stays is a pivotal factor poised to contribute significantly to the market's growth. Remarkably, continuous subcutaneous (SC) apomorphine infusion emerges as an exceptionally effective treatment for Parkinson's disease (PD), with diverse drug formulations available for the management of PD through subcutaneous delivery. In response to the mounting burden of PD, there is a notable surge in the demand for subcutaneous infusion therapy. For instance, in line with the Parkinson's Foundation's 2022 data update, approximately 90,000 individuals receive a PD diagnosis annually in the U.S. Furthermore, the anticipated number of people living with PD in the country is projected to soar to nearly 1.2 million by the year 2030.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global knee braces market size was valued at USD 1.12 billion in 2023 and is projected to grow at a CAGR of 7.7% from 2024 to 2030.
• The global western blotting market size was valued at USD 986.2 million in 2023 and is projected to grow at a CAGR of 6.1% from 2024 to 2030.

Key Companies Market Share Insights

Some of the key players operating in the market include Baxter, BD, Smiths Medical, Terumo Corporation, ICU Medical, etc

Baxter International Inc., commonly known as Baxter, is a global healthcare company that specializes in providing a wide range of medical products, therapies, and technologies. With a rich history dating back to the 1930s, Baxter has evolved into a leading player in the healthcare industry. The company develops innovative solutions for critical medical needs, including renal care, medication delivery, pharmaceuticals, and various therapeutic areas.

Becton, Dickinson and Company (BD) is a global medical technology company. BD specializes in developing and manufacturing medical devices, laboratory equipment, and diagnostic products aimed at advancing the diagnosis and treatment of various medical conditions. With a commitment to improving healthcare outcomes, BD focuses on delivering solutions in areas such as medication management, infection prevention, diagnostics, and biosciences.

Key Home Infusion Therapy Companies:

• CVS/Coram
• Option Care Health
• BriovaRx/Diplomat (UnitedHealth Optum)
• PharMerica
• Fresenius Kabi
• ICU Medical, Inc.
• Braun Melsungen AG
• Baxter
• BD
• Caesarea Medical Electronics
• Smiths Medical
• Terumo Corporation
• JMS Co. Ltd.

Recent Developments

In June 2023, Baxter International, an American healthcare company, introduced Progressa+ Next Gen ICU bed for addressing critical needs of patients at their homes. This technology makes it easier for nurses to take care of patients, while supporting therapy at home.

In May 2023, Fresenius Kabi, a global healthcare company, initiated an agreement with Premier, Inc., an American healthcare company, that resulted in pricing and term benefits for the Ivenix Infusion System. This system is designed to advance the reliability and simplicity of infusion pumps.

In May 2023, Option Care Health, a healthcare service provider, created an independent platform for home care services in collaboration with Amedisys Inc., a leading provider of home health services. This platform comprises pharmacists, dieticians, therapists, social workers, and others for providing high quality healthcare services at home.

In April 2023, CareFusion, currently owned by Becton Dickinson, an American medical technology company, launched an advanced ultrasound technology to provide clinicians with optimal IV insertions. More than 90% hospitalized patients receive the IV therapy, thus contributing towards the market growth of home infusion therapy.

In January 2022, ICU Medical, a California-based global operations company, finalized the acquisition of Smiths Medical from Smiths Group Plc for creating a leading infusion therapy company with a combined revenue of USD 2.5 billion.

In November 2021, Terumo Corporation, a global medical device company, developed a smartphone device for controlling insulin pump. This device can be utilized as a home infusion therapy by patients for harmonizing the insulin therapy at home.

Order a free sample PDF of the Home Infusion Therapy Market Intelligence Study, published by Grand View Research.